NCT00267683View on ClinicalTrials.gov

Efficacy and Safety of Insulin Aspart Versus Glibenclamide in Type 2 Diabetes

PHASE3TerminatedINTERVENTIONAL

Enrollment

9

Participants

Timeline

Start Date

December 31, 2005

Primary Completion Date

April 30, 2006

Study Completion Date

April 30, 2006

Conditions

DiabetesDiabetes Mellitus, Type 2

Interventions

DRUG

insulin aspart

DRUG

glibenclamide

Sponsors

Lead Sponsor

Novo Nordisk A/S

All Listed Sponsors

lead

Novo Nordisk A/S

INDUSTRY